ArticleNature cancer2020
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 79 citations in OpenAlex.
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.Cell reports. Medicine · 2026Article
- A pan-cancer single-cell transcriptomic atlas of human bone metastases.Cell reports. Medicine · 2026Article
- Missense and Intronic Variants inInternational journal of medical sciences · 2026Article
- FBXL22, a circadian-regulated immune biomarker with pan-cancer prognostic value and therapeutic potential in prostate cancer.Oncology letters · 2025Article
- ATAD2 Drives Prostate Cancer Progression to Metastasis.Molecular cancer research : MCR · 2025Article
- Targeting ADAR1 with a small molecule for the treatment of prostate cancer.Nature cancer · 2025Article
- Intratumour oxidative hotspots provide a niche for cancer cell dissemination.Nature cell biology · 2025Article
- CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.Oncogene · 2025Article
- Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.Cancer metastasis reviews · 2025Review
- Interactions between key genes and pathways in prostate cancer progression and therapy resistance.Frontiers in oncology · 2025Review
- Application and new findings of scRNA-seq and ST-seq in prostate cancer.Cell regeneration (London, England) · 2024Review
- Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer.Cancer discovery · 2024Article
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends in cancer · 2024Review
- Mouse Models of Metastasis and Dormancy.Cold Spring Harbor perspectives in medicine · 2024Review
- Mechanical stress during confined migration causes aberrant mitoses and c-MYC amplification.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.Cancer letters · 2024Review
- Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.Science advances · 2024Article
- In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.Oncogene · 2024Article
- CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 4 countries.
Juan M ArriagaDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7523-2955
Sukanya PanjaDepartment of Health Informatics, Rutgers School of Health Professions, Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Mohammed AlshalalfaDepartment of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8405-3035
Junfei ZhaoDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
Min ZouDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Arianna GiacobbeDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Chioma J MadubataDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
Jaime Yeji KimDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Antonio RodriguezDepartment for BioMedical Research, University of Bern and Inselspital, Bern, Switzerland.
Ilsa ColemanFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Renu K VirkDepartment of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Hanina HibshooshDepartment of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Onur ErtuncDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4159-1711
Büşra OzbekDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julia FountainDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Jun LuoDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Emmanuel S AntonarakisDepartment of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter S NelsonFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Felix Y FengDepartment of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0963-7687
Mark A RubinDepartment for BioMedical Research, University of Bern and Inselspital, Bern, Switzerland.ORCID http://orcid.org/0000-0002-8321-9950
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Raul RabadanDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7946-9255
Peter A SimsDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
Antonina MitrofanovaDepartment of Health Informatics, Rutgers School of Health Professions, Rutgers Biomedical and Health Sciences, Newark, NJ, USA. amitrofa@shp.rutgers.edu.ORCID http://orcid.org/0000-0003-0671-6512
Cory Abate-ShenDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA. cabateshen@columbia.edu.ORCID http://orcid.org/0000-0002-5021-0570
Columbia University Irving Medical Center · USJohns Hopkins University · USFred Hutch Cancer Center · USRutgers, The State University of New Jersey · USUniversity of Bern · CHUniversity of California, San Francisco · USMayo Clinic in Arizona · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MSystematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MFunctional Determinants of Metastatic DormancyR01CA109182 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI AGUIRRE-GHISO, JULIO A. · 2005 to 2025
$8.3MPreclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1MMolecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1MInvestigating the cell of origin for bladder cancerR01CA193442 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2019
$2.4MEpigenetic and microenvironmental regulation of dormant disseminated cancerR01CA218024 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGUIRRE-GHISO, JULIO A., BERNSTEIN, EMILY · 2017 to 2021
$2.2MDefining the role of type III collagen and the collagen-binding receptor DDR1 in metastatic dormancyR01CA244780 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRAVO-CORDERO, JOSE JAVIER · 2020 to 2024
$1.9MNCATS NIH HHS UL1 TR001873NCI NIH HHS F31 CA210607NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA097186NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA109182NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R01 CA193442NCI NIH HHS R01 CA218024NCI NIH HHS R01 CA244780NCI NIH HHS U54 CA209997
Abstract
Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that
Indexed as
Bone NeoplasmsProstatic NeoplasmsAnimalsCastrationGene Expression Regulation, NeoplasticHumansMaleMiceTranscription FactorsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.